Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA's 17th Annual Pain Medicine Meeting

November 14, 2018

RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia") , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, announced that safety, pharmacokinetics and pharmacodynamic results from its Phase 1a study in healthy volunteers of LIQ865 will be presented at The American Society of Regional Anesthesia and Pain Medicine's (ASRA) 17 th Annual Pain Medicine Meeting, being held in San Antonio, Texas. LIQ865 is an injectable, sustained-release formulation of bupivacaine, a non-opioid anesthetic, for the management of local post-operative pain for three to five days through a single administration.

Details on the scientific presentation are listed below. The presentation will be available on the Publications page of Liquidia's website following its presentation at ASRA's 17 th Annual Pain Medicine Meeting.

Title: "A Phase 1 Randomized, Controlled, Double-Blind, Single Ascending Dose Safety and Pharmacokinetic/Pharmacodynamic Study in Healthy Adult Males after LIQ865 Injection"
Presentation Number: 6323
Session Name: Emerging Technology
Date and Time: Friday, November 16, 2018 at 10:30 – 12:15 p.m. CST
Presenter: Mads Werner, MD, PhD, DMSc, Multidisciplinary Pain Center, Neuroscience Center, Copenhagen University Hospitals, Denmark

About Liquidia Technologies

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT® technology. For more information visit our website at www.liquidia.com.

Contact:
Jennifer Almond
Director, Investor Relations & Corporate Communications
919.328.4389
IR@liquidia.com

Source: Liquidia Technologies, Inc.